Hutchison Medicine and AstraZeneca initiate phase 3 clinical trials of combination therapy in China

On November 24, 2021, HUTCHMED and AstraZeneca announced that they have launched a Phase 3 clinical trial in China

Lung cancer accounts for about one-fifth of all cancer deaths

In China, Teresa was first approved for second-line treatment of EGFR-T790M mutation-positive advanced NSCLC patients in March 2017, and was approved for first-line treatment of EGFR mutation-positive advanced NSCLC patients in October 2019

And MET is a receptor tyrosine kinase

Waresa has been approved for marketing in China for the treatment of NSCLC patients with a jump mutation in MET exon 14 who have undergone systemic therapy or who have undergone disease progression or who cannot receive chemotherapy

This open-label, randomized controlled, multi-center phase 3 clinical trial will be carried out in locally advanced or metastatic NSCLC with disease progression and MET amplification after receiving EGFR inhibitor treatment.

Reference materials:

[1] HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of Certain ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy.

[2] Hutchison Medical and AstraZeneca initiated the SACHI China Phase III clinical trial of the combined therapy of ORPATHYS® (ORPATHYS®) and Teresa® (TAGRISSO®) in the treatment of specific lung cancer patients with disease progression after EGFR inhibitor treatment.